文献速递白血病造血干细胞移植与细胞治疗

儿童急性髓系白血病幸存者的晚期结局:圣犹达终身队列研究报告

Late outcomes in survivors of childhood acute myeloid leukemia: a report from the St. Jude Lifetime Cohort Study.
PubMed 文献 · Leukemia · 2021-01-25

该研究评估了接受造血干细胞移植(HCT,n=66)或常规治疗(CT,n=67)的儿童急性髓系白血病(AML)幸存者的慢性健康问题累积负担及神经认知与躯体功能。至40岁时,HCT和CT幸存者平均分别有17.4和9.3种1-4级健康问题,而社区对照为3.8种;HCT幸存者高甘油三酯血症、高胆固醇血症、甲状腺功能减退和原发性性腺功能减退患病率更高,CT幸存者心肌病和高血压患病率更高;所有领域的神经认知损伤均高于对照但不同治疗方式间无差异。

要点

  • 至40岁,HCT幸存者平均有17.4种1-4级慢性健康问题,CT幸存者为9.3种,均远高于对照的3.8种。
  • HCT幸存者内分泌代谢异常(高甘油三酯血症、高胆固醇血症、甲减、性腺功能减退)显著更常见。
  • CT幸存者心肌病(11.9% vs 2.7%)和高血压(53.7% vs 44.3%)患病率高于对照。

核心结论

  • 儿童AML幸存者晚期慢性健康问题负担重,HCT幸存者负担高于CT幸存者,均远高于社区对照。
  • 神经认知损伤普遍存在且与治疗方式无关,提示需关注所有幸存者的神经认知结局。

研究设计与样本

  • 圣犹达终身队列研究,纳入儿童AML幸存者HCT组n=66、CT组n=67,并进行综合临床评估。
  • 健康问题采用修改版常见不良事件术语标准(CTCAE)分级,并与社区对照比较。

主要发现

  • 至40岁,HCT和CT幸存者平均分别有17.4(95%CI 14.6-20.1)和9.3(7.7-11.1)种1-4级健康问题,对照为3.8(3.3-4.2)种。
  • HCT幸存者高甘油三酯血症45.5% vs 对照18.3%,高胆固醇血症47.0% vs 30.9%,甲减27.3% vs 4.0%,原发性性腺功能减退p<0.001。
  • CT幸存者心肌病11.9% vs 对照2.7%,高血压53.7% vs 44.3%。
  • 神经认知损伤在所有领域均高于对照但HCT与CT无差异;HCT幸存者力量和耐力受损更明显,CT幸存者柔韧性和移动性受损更明显。

临床怎么用

  • 儿童AML幸存者应长期监测慢性健康问题,HCT幸存者重点筛查内分泌代谢异常,CT幸存者重点筛查心血管疾病。
  • 所有幸存者均应评估神经认知功能,并针对力量、耐力或柔韧性、移动性进行个体化康复指导。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cumulative burden of chronic health conditions and neurocognitive and physical function were examined among survivors of childhood acute myeloid leukemia (AML) treated with hematopoietic cell transplant (HCT; n = 66) or conventional therapy (CT; n = 67). Survivors and controls underwent a comprehensive clinical assessment, and health conditions were graded using a modified version of the Common Terminology Criteria for Adverse Events. By age 40 years, HCT and CT survivors had an average 17.4 (95% confidence interval [CI] 14.6-20.1) and 9.3 (7.7-11.1) grade 1-4 conditions versus 3.8 (3.3-4.2) in community controls. Compared to controls, HCT survivors had a higher prevalence of hypertriglyceridemia (45.5% vs. 18.3%), hypercholesterolemia (47.0% vs. 30.9%), hypothyroidism (27.3% vs. 4.0%), and primary hypogonadism (p < 0.001). CT survivors had a higher prevalence of cardiomyopathy (11.9% vs. 2.7%) and hypertension (53.7% vs. 44.3%). Neurocognitive impairment was elevated across all domains compared to controls but did not differ by treatment modality. Compared to controls, a higher proportion of HCT survivors had impairments in strength and endurance; whereas flexibility and mobility impairments were noted among CT survivors. Despite successful advances in childhood AML therapy, many therapeutic exposures remain unchanged. These findings support ongoing investigations of novel therapies and strategies to ameliorate the risk of late morbidities.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Bhatt NS, Baassiri MJ, Liu W, et al. Late outcomes in survivors of childhood acute myeloid leukemia: a report from the St. Jude Lifetime Cohort Study. Leukemia. 2021. PMID: 33495497. doi:10.1038/s41375-021-01134-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。